Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 11, 2007, Pages 4919-4923

  Van Gils, Walter ^a   Mensink, Hanneke W ^b   Kilic, Emine ^a   Vaarwater, Jolanda ^b   Verbiest, Michael M ^a   Paridaens, Dion ^b   Luyten, Gregorius P ^a,c   De Klein, Annelies ^a   Brüggenwirth, Hennie T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APITD1 PROTEIN; DNA; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; APITD1 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME 3; CHROMOSOME NUMBER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UVEA MELANOMA; APOPTOSIS; CELL CULTURE; CHROMOSOME 1; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA TUMOR;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 3; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UVEAL NEOPLASMS;

EID: 38449120296     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0061     Document Type: Article

References (23)

1. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-961.
2. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46:2253-2257.
3. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:313-317.
4. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334:225-230.
5. Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 2002;9:246-251.
6. Hughes S, Damato BE, Giddings I, et al. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer. 2005;93:1191-1196.
7. Ejeskar K, Sjoberg RM, Abel F, et al. Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol. 2001;36:61-66.
8. Lu H, Levine AJ. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA. 1995;92:5154-5158.
9. Krona C, Ejeskar K, Caren H, Abel F, Sjoberg RM, Martinsson T. A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours. Br J Cancer. 2004;91:1119-1130.
10. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157:1795-1801.
11. Naus NC, Zuidervaart W, Rayman N, et al. Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int J Cancer. 2000;87:151-153.
12. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997;73:470-478.
13. Luyten GP, Naus NC, Mooy CM, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer. 1996;66:380-387.
14. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829-834.
15. De Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995;62:155-161.
16. Hagemeijer A, de Klein A, Wijsman J, van Meerten E, de Greef GE, Sacchi N. Development of an interphase fluorescent in situ hybridization (FISH) test to detect t(8;21) in AML patients. Leukemia. 1998;12:96-101.
17. Hopman AH, Ramaekers FC, Raap AK, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry. 1988;89:307-316.
18. van Dekken H, Pizzolo JG, Reuter VE, Melamed MR. Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome-specific DNA probes. Cytogenet Cell Genet. 1990;54:103-107.
19. Caren H, Ejeskar K, Fransson S, et al. A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer. 2005;4:10.
20. Abel F, Sjoberg RM, Krona C, Nilsson S, Martinsson T. Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. Int J Oncol. 2004;25:1297-1302.
21. Abel F, Sjoberg RM, Ejeskar K, Krona C, Martinsson T. Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. Br J Cancer. 2002;86:596-604.
22. Krona C, Ejeskar K, Abel F, et al. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene. 2003;22:2343-2351.
23. Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36. Cell. 2007;128:459-475.